A novel human T-cell platform to define biological effects of genome editing
A novel human T-cell platform to define biological effects of genome editing
批准号:
10434027
负责人:
Shengdar Tsai
金额:
$61.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-12 至 2024-06-30
关键词:
AddressAdvanced DevelopmentAdverse effectsAffectArtificial IntelligenceBar CodesBenignBiochemicalBioinformaticsBiologicalBiological AssayCell modelCell physiologyCellsChromatinClonal ExpansionComplexCoupledDNA MethylationDetectionEngineeringEpitopesFrequenciesGene ExpressionGenesGeneticGenetic DiseasesGenetic TranscriptionGenetic VariationGenomeGenomic medicineGenomicsGoalsHIVHumanHuman GeneticsHuman GenomeImmunologic Deficiency SyndromesIn VitroInheritedMalignant NeoplasmsMapsMature T-LymphocyteMeasuresMethodsModelingMutationOncogenicOrganizational ChangeOutcomePeptide LibraryPeripheral Blood Mononuclear CellPhenotypePopulationProto-OncogenesRegulatory ElementRetroviral VectorRibonucleoproteinsSafetySiteSite-Directed MutagenesisStandardizationStreptococcus pyogenesT cell receptor repertoire sequencingT cell responseT-Cell ProliferationT-LymphocyteT-cell receptor repertoireTechnologyTestingTherapeuticTrainingVariantadaptive immune responseadverse outcomebasebase editorcomparative genomicscytokinedeep learning modeldetection limiteffective therapyepigenomicsfunctional genomicsgene therapygenome editinggenome-widegenotoxicityhistone modificationhuman diseaseimmunogenicimmunogenicityimprovedin vivomachine learning methodnext generationnovelnovel therapeuticsoff-target mutationoff-target siteresponsesafety assessmentsafety testingside effecttherapeutic developmenttherapeutic genetherapeutic genome editingtranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Genome editing technologies have extraordinary potential as new genomic medicines that address underlying
genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we
do not know the consequences of potential side effects of genome editing such as off-target mutations or
immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance
the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly
relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell-based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can
be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific
treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have
biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with
state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional
effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity,
or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence
in the safety of the next generation of promising genome editing therapies.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/s41587-022-01328-9
发表时间:
2022-08
期刊:
Nature biotechnology
影响因子:
46.9
作者:
[Nahmad AD, Lazzarotto CR, Zelikson N, Kustin T, Tenuta M, Huang D, Reuveni I, Nataf D, Raviv Y, Horovitz-Fried M, Dotan I, Carmi Y, Rosin-Arbesfeld R, Nemazee D, Voss JE, Stern A, Tsai SQ, Barzel A]
通讯作者:
Barzel A
DOI:
10.1038/s41596-021-00626-x
发表时间:
2021-12
期刊:
NATURE PROTOCOLS
影响因子:
14.8
作者:
[Malinin, Nikolay L., Lee, GaHyun, Lazzarotto, Cicera R., Li, Yichao, Zheng, Zongli, Nguyen, Nhu T., Liebers, Matthew, Topkar, Ved V., Iafrate, A. John, Le, Long P., Aryee, Martin J., Joung, J. Keith, Tsai, Shengdar Q.]
通讯作者:
Tsai, Shengdar Q.
DOI:
10.1089/crispr.2023.0033
发表时间:
2023-09
期刊:
The CRISPR journal
影响因子:
--
作者:
[Kaivalya Molugu;Namita Khajanchi;C. Lazzarotto;S. Tsai;Krishanu Saha]
通讯作者:
Kaivalya Molugu;Namita Khajanchi;C. Lazzarotto;S. Tsai;Krishanu Saha
DOI:
10.1186/s13059-021-02458-0
发表时间:
2021-08-19
期刊:
Genome biology
影响因子:
12.3
作者:
[Li Y, Chen J, Tsai SQ, Cheng Y]
通讯作者:
Cheng Y
DOI:
10.3389/fimmu.2022.1067417
发表时间:
2022
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[Brault J, Liu T, Liu S, Lawson A, Choi U, Kozhushko N, Bzhilyanskaya V, Pavel-Dinu M, Meis RJ, Eckhaus MA, Burkett SS, Bosticardo M, Kleinstiver BP, Notarangelo LD, Lazzarotto CR, Tsai SQ, Wu X, Dahl GA, Porteus MH, Malech HL, De Ravin SS]
通讯作者:
De Ravin SS
共 6 条
Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs
-
批准号:10668823
-
项目类别:
-
资助金额:$47.91万
-
财政年份:2023
-
负责人:Shengdar Tsai
-
依托单位:
Ultra-sensitive, unbiased, high-throughput, biochemical CHANGE-seq genome-wide activity and gRNA sequencing assays for therapeutic genome editing INDs
-
批准号:10668824
-
项目类别:
-
资助金额:$47.91万
-
财政年份:2023
-
负责人:Shengdar Tsai
-
依托单位:
A novel human T-cell platform to define biological effects of genome editing
-
批准号:10016298
-
项目类别:
-
资助金额:$61.07万
-
财政年份:2018
-
负责人:Shengdar Tsai
-
依托单位:
A novel human T-cell platform to define biological effects of genome editing
-
批准号:10202452
-
项目类别:
-
资助金额:$61.01万
-
财政年份:2018
-
负责人:Shengdar Tsai
-
依托单位:
Improving the Efficiency of Gene Targeting Using TAL Effector Nucleases
-
批准号:8609491
-
项目类别:
-
资助金额:$5.51万
-
财政年份:2013
-
负责人:Shengdar Tsai
-
依托单位:
Improving the Efficiency of Gene Targeting Using TAL Effector Nucleases
-
批准号:8456449
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2013
-
负责人:Shengdar Tsai
-
依托单位:
海外基金